DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CADUET

Summary for Tradename: CADUET

Patents:4
Applicants:1
NDAs:1
Suppliers: see list5
Formulation / Manufacturing:see details
drug
patent expirations by year for
 CADUET

Clinical Trials for: CADUET

Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Status: Completed Condition: Hypertension; Angina Pectoris; Hypercholesterolemia; Familial Hypercholesterolemia

Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Status: Completed Condition: Hypertension; Hypercholesterolemia; Angina Pectoris

Caduet in an Untreated Subject Population
Status: Completed Condition: Hypertension; Dyslipidemia

Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
Status: Terminated Condition: Hypertension and Cardiovascular Risk Factors

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Status: Completed Condition: Hypertension; Hypercholesterolemia

Cardiovascular Risk Assessment in Patients Treated With Caduet
Status: Completed Condition: Hypertension

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
Status: Completed Condition: Hypertension; Dyslipidemia

Amlodipine Plus/Minus Atorvastatin for Protection of Arteries
Status: Recruiting Condition: Arterial and Arteriolar Disorders

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
Status: Completed Condition: Dyslipidemia; Hypertension

A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin
Status: Completed Condition: Hypertension; Hypercholesterolemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
CADUET
amlodipine besylate; atorvastatin calcium
TABLET;ORAL021540Jan 30, 2004RXNo5,686,104*PED<disabled>Y<disabled>
Pfizer
CADUET
amlodipine besylate; atorvastatin calcium
TABLET;ORAL021540Jan 30, 2004RXNo5,969,156*PED<disabled>Y<disabled>
Pfizer
CADUET
amlodipine besylate; atorvastatin calcium
TABLET;ORAL021540Jan 30, 2004RXNo6,126,971*PED<disabled><disabled>
Pfizer
CADUET
amlodipine besylate; atorvastatin calcium
TABLET;ORAL021540Jan 30, 2004RXNo6,455,574<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CADUET

Drugname Dosage Strength RLD Submissiondate
amlodipine besylate and atorvastatin calciumTablets2.5 mg/40 mgCaduet9/17/2009
amlodipine besylate and atorvastatin calciumTablets5 mg/80 mgCaduet4/7/2009
amlodipine besylate and atorvastatin calciumTablets5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mgCaduet12/29/2006

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc